Aim: We aimed to characterize the safety profile of pembrolizumab in advanced melanoma patients at our center to better reflect ‘real-world’ data on anti-PD-1 inhibitors. Materials & methods: At our institution, 58 ipilimumab-naive and 30 ipilimumab-treated patients with advanced melanoma who have received pembrolizumab between June 2014 and June 2017 were included for analysis. Results: Incidence of any-grade and grade 3/4 toxicities were 81.8% (n = 72) and 12.5% (n = 11), respectively.
